Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 15.9%, EPS grew 38.1%, free cash flow grew 211.3% and total debt rose 6.44%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow XGN
Exagen Inc. (XGN) EV/Sales
As of 16 October 2026, Exagen Inc. (XGN) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from −0.9× (October 2019) to 5.9× (March 2021); the current reading is higher than 74% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | 41.65% |
| FY2024 | 1.3× | 286.68% |
| FY2023 | 0.3× | 79.81% |
| FY2022 | 0.2× | (92.03%) |
| FY2021 | 2.4× | (27.05%) |
| FY2020 | 3.2× | 191.93% |
| FY2019 | 1.1× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.6× | 44.44% |
| Mar 2026 | 1.1× | (41.21%) |
| Dec 2025 | 1.9× | (51.07%) |
| Sep 2025 | 3.8× | 59.54% |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MYGN Myriad Genetics, Inc. compare | 0.5× |
| MDXH MDxHealth SA compare | 0.8× |
| FLGT Fulgent Genetics, Inc. compare | 1.0× |
| BDSX Biodesix, Inc. compare | 2.5× |
| XGN Exagen Inc. | 2.6× |
| QUCY Quantum Cyber N.V compare | 8.4× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 17.9× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. compare | 55.7× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)